We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02401347
Recruitment Status : Active, not recruiting
First Posted : March 27, 2015
Last Update Posted : November 21, 2022
BioMarin Pharmaceutical
Information provided by (Responsible Party):
Melinda Telli, Stanford University

Brief Summary:
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

Condition or disease Intervention/treatment Phase
Advanced Breast Cancer HER2/Neu Negative Triple-Negative Breast Cancer Drug: Talazoparib Tosylate Phase 2

Detailed Description:

Talazoparib (BMN 673) is a novel, dual-mechanism PARP inhibitor that potently inhibits the PARP enzyme and effectively traps PARP on DNA. Talazoparib has shown promising single-agent anti-tumor efficacy in several BRCA1/2 mutation-associated advanced cancers. The efficacy of PARP inhibition in BRCA1/2 wild-type TNBC with homologous recombination (HR) defects and in breast tumors with mutations in other non-BRCA1/2 HR pathway genes is currently unknown.

This phase 2 trial explores the activity of single agent talazoparib in BRCA1/2 wild-type BC patients using an optimal Simon two-stage design. Eligible subjects will be assigned to one of two parallel cohorts: 1) Cohort A: Subjects (n=29) with advanced TNBC with underlying HR defects as assessed by the HRD assay and, 2) Cohort B: Subjects (n=29) with advanced HER2-negative BC with a somatic or germline mutation in a non-BRCA1/2 HR pathway gene. Gene mutations of interest are: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes (FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes
Actual Study Start Date : August 2015
Actual Primary Completion Date : December 23, 2019
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Talazoparib

Arm Intervention/treatment
Experimental: Cohort A - Triple-negative Breast Cancer

Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.

Participants receive talazoparib 1 mg by mouth daily.

Drug: Talazoparib Tosylate
Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Other Name: BMN 673

Experimental: Cohort B - HER2-negative solid tumor

Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:

PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.

Participants receive talazoparib 1 mg by mouth daily.

Drug: Talazoparib Tosylate
Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Other Name: BMN 673

Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 3 years ]
    Objective response rate (ORR) will be assessed and is defined as complete response or partial response per RECIST 1.1

Secondary Outcome Measures :
  1. Clinical benefit rate [ Time Frame: After at least 24 weeks ]
    Clinical benefit rate ≥ 24 weeks will be assessed and is defined as complete response, partial response or stable disease as assessed after at least 24 weeks per RECIST 1.1

  2. Progression-free survival (PFS) [ Time Frame: From randomization to documented disease progression or death ]
  3. Incidence of adverse events, graded according to CTCAE v4.0 [ Time Frame: Up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • No deleterious germline BRCA1 or BRCA2 mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory; patients with variants of unknown significance will be eligible
  • Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
  • Must have progressed on at least 1 prior chemotherapy regimen for the treatment of advanced breast cancer; there is no upper limit on the number of prior therapies
  • If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT ≤ 5 x ULN
  • Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome)
  • Calculated creatinine clearance ≥ 30 mL/min or serum creatinine ≤ 1.5 mg/dL
  • Hemoglobin ≥ 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
  • Absolute neutrophil count (ANC) ≥ 1500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Able to take oral medications
  • Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
  • Sexually active patients of childbearing potential must be willing to use an acceptable method of contraception such as an intrauterine device or double barrier contraception during treatment and for 30 days after the last dose of study drug
  • Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to have additional serum pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy
  • Willing and able to comply with all study procedures

    • Histologically-confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor ≤ 5%, progesterone receptor ≤ 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH])
    • An homologous recombination deficiency (HRD) score ≥ 42 on the HRD Assay as assessed on a tumor biopsy sample; in the case that obtaining an adequate metastatic tumor biopsy is not possible, we will assess the HRD score from the primary breast tumor

    • Histologically-confirmed metastatic or recurrent HER2-negative (via IHC or FISH) breast cancer or other histologically-confirmed metastatic solid tumor
    • Deleterious germline or somatic mutation implicated in the homologous recombination (HR) pathway, excluding BRCA1 or BRCA2, based on germline multiplex gene testing or direct tumor next generation DNA sequencing. Genes of interest include: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.


  • Any patient with a deleterious mutation in BRCA1 or BRCA2
  • Hormone receptor positive and/or HER2 positive breast cancer (Cohort A only)
  • HER2 positive breast cancer (Cohort B only)
  • Prior treatment with a PARP inhibitor
  • Non-measurable disease only
  • Pregnant or nursing patients
  • Any anti-cancer therapy within the past 21 days of the first day of treatment
  • Brain or central nervous system (CNS) metastases

    • Exception: Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases
    • Subjects with leptomeningeal carcinomatosis are not permitted
  • Other malignancy that is either active or for which patient has received treatment in the last five years excluding non-melanoma skin cancer and carcinoma in situ of the cervix
  • Radiation therapy in the last 14 days
  • Known to be human immunodeficiency virus positive
  • Known active hepatitis C virus
  • Known active hepatitis B virus
  • Use of any investigational product or investigational medical device within 28 days before day 1 of study drug
  • Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug
  • Concurrent disease or condition that would interfere with study participation or safety, such as any of the following:

    • Active, clinically significant infection either grade > 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 or requiring the use of parenteral anti-microbial agents within 7 days before day 1 of study drug
    • Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
    • Known hypersensitivity to any of the components of BMN 673

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02401347

Layout table for location information
United States, California
Stanford University Hospitals and Clinics
Stanford, California, United States, 94305
Sponsors and Collaborators
Melinda Telli
BioMarin Pharmaceutical
Layout table for investigator information
Principal Investigator: Melinda L. Telli, M.D. Stanford University
Layout table for additonal information
Responsible Party: Melinda Telli, Assistant Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT02401347    
Other Study ID Numbers: IRB-31913
NCI-2015-00036 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
BRS0050 ( Other Identifier: OnCore )
First Posted: March 27, 2015    Key Record Dates
Last Update Posted: November 21, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Melinda Telli, Stanford University:
PALB2 mutation
BRIP1 mutation
BARD1 mutation
Rad51c mutation
PTEN mutation
CHEK2 mutation
ATM mutation
NBN mutation
Rad51d mutation
Rad50 mutation
MRE11 mutation
FANC mutation
HRD assay score
ATR mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents